Author:
Lorier Marianela,Fagiolino Pietro
Publisher
Springer International Publishing
Reference17 articles.
1. Ludden TM. Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet. 1991;20:429–46. https://doi.org/10.2165/00003088-199120060-00001.
2. Xu C, Li CY-T, Kong A-N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005;28:249–68. https://doi.org/10.1007/BF02977789.
3. Rambeck BJU, May T. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and Comedication. Ther Drug Monit. 1987;9:298–303. https://doi.org/10.1097/00007691-198709000-00008.
4. Fagiolino P, Vázquez M, Olano I, Delfino A. Systemic and presystemic conversion of carbamazepine to carbamazepine-10,11-epoxide during long term treatment. J Epilepsy Clin Neurophysiol. 2006;12:13–6. https://doi.org/10.1590/s1676-26492006000100004.
5. Maldonado C, Fagiolino P, Vázquez M, Eiraldi R, Alvariza S, Bentancur C, Álvarez P. Time-dependent and concentration-dependent upregulation of carbamazepine efflux transporter. A preliminary assessment from salivary drug monitoring. Lat Am J Pharm. 2001;30:908–12. http://sedici.unlp.edu.ar/handle/10915/8235